New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) - Wikidata - thesis-toulmin - TriplyDB

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

http://www.wikidata.org/entity/Q28131668

about

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies Radiomics: extracting more information from medical images using advanced feature analysis Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia Immunotherapy for metastatic renal cell carcinoma Sipuleucel-T for metastatic castration-resistant prostate cancer Maintenance therapy for advanced non-small cell lung cancer (NSCLC)Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer Gemcitabine-based chemotherapy for advanced biliary tract carcinomas Medical interventions for high-grade vulval intraepithelial neoplasia Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma External beam radiotherapy for unresectable hepatocellular carcinoma Capecitabine for ER-positive versus ER-negative breast cancer Chemotherapy for thymic carcinoma and advanced thymoma in adults Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer Chemotherapy for thymic carcinoma and advanced thymoma in adults Cisplatin versus carboplatin in association with third-generation drugs for advanced non-small cell lung cancer Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma Cancer pharmacogenomics: strategies and challenges Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients Improved endpoints for cancer immunotherapy trials FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma Dendritic cell vaccines for brain tumors Sipuleucel-T for metastatic castration-resistant prostate cancer Bone Density as a Marker of Response to Radiotherapy in Bone Metastatic Lesions: A Review of the Published Data The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Imaging Procedures for Colorectal Cancer A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents New targeted treatments for non-small-cell lung cancer - role of nivolumab Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Challenges in translating endpoints from trials to observational cohort studies in oncology New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review.

P2860

Q21245463-7D2BC78C-71D5-4870-8523-A3245F04CBA8 Q21245492-10C7ECEE-D491-401A-A77B-6EBB4E3E8211 Q23760733-A23BE41E-CAE5-42EB-8C43-6AEA2D0232FA Q24186130-A9AAB38C-A6E0-4455-B126-31134C2A3FC5 Q24186582-B81C1CDE-5C3B-4C0B-BF7C-C5E9C3AC6090 Q24186688-55A3A95A-A28D-4A2F-A942-9323D61886BD Q24186731-7FC8B2EF-7EEF-482D-BBBB-EBE147BC8DE2 Q24186793-29BC38A5-94D5-45E6-900E-8F3298F05AFC Q24187473-8743D0D4-66E6-4FB1-BFB5-0B3F991CDB74 Q24187573-091EC01C-3A77-47C5-AF5B-5EAFCC3A209B Q24187846-9E794698-AB56-42C1-9057-9EAFF635EFC3 Q24192969-2D8053D8-823F-4307-9911-0B6E958B7B6B Q24194017-46A2D757-EEE0-4A2B-BF00-9E9AA31A5EA8 Q24194024-C386096E-5E52-4672-8BA6-4FA42F82BC2B Q24194664-3043FCFC-89D9-411D-8A3B-D7D074C6D6DC Q24200260-FECA1411-D75C-4749-93A2-88B97744F9D4 Q24200413-D534FCB4-33A0-4CBA-A41B-F7ED4D26D1D5 Q24201772-13B96B7B-E30F-483B-8CFA-424D80E8BA1D Q24234500-0372E332-D0F3-4816-B8F0-79E4F6929482 Q24235240-685104D3-1054-4847-8111-CFB67C1FA551 Q24235977-B0F87E7C-C736-4F99-8A66-417DA69E2D59 Q24289309-5B95ADCF-E549-42C4-82A5-38B9047CA6C2 Q24594790-8BE0C2E8-0954-4BA0-813B-3DB4A6CDA98C Q24598792-D5ADC0C7-9C3E-4C74-9A27-3D531CAB4090 Q24603112-56BD962C-97E0-4130-8E77-D1C24538C543 Q24622390-F300FAFA-7790-438F-A967-7E428AF322DD Q24635643-D066128B-16A3-46CD-BB70-0465212A816D Q24641823-5048D6DD-C757-4A80-BCCB-CBC50487276F Q26471816-F8A0F44B-DDBA-4CE8-B69A-056801331566 Q26738637-D59C8C41-2DE3-4A28-B1DD-ADABD42FD21E Q26738677-8D3F83D6-391C-40ED-A73D-01C4DD4DBE49 Q26738809-AF034CEF-E47A-41CF-9D7E-F61144A65BAD Q26739607-5569F955-AD74-4458-9B38-73477C5C1C06 Q26740567-8EB659CE-AD46-4193-8D98-3350A406CDE4 Q26740988-335E8D22-DB91-4B68-8E8C-902691051007 Q26741729-F1E668D8-1E4B-4347-B625-788047896C11 Q26745427-B21B9C4B-87DC-41EE-8AAA-A604DBB77116 Q26746190-86388712-F80B-4116-8238-544CB068A28E Q26746230-0A08745A-999B-4F53-976F-0D160473170D Q26749119-AF37C11D-B3A1-4044-AEB9-7CF1BD0C1EC1

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

http://www.wikidata.org/entity/Q28131668

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@ast

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@en

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@nl

type

label

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@ast

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@en

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@nl

prefLabel

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@ast

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@en

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@nl

P1433

Q28131668-320C93AB-64BA-48DF-A602-8E09724F0EA3

P1476

Q28131668-E3F09E35-04D1-4684-8BE4-7DF41ACAD0B9

P2093

Q28131668-0C6E384A-A6B1-4EC0-BCD5-819293AF5129

Q28131668-0D634441-86FE-478E-9AEB-5C6116A07829

Q28131668-1537D68B-7EB3-42E8-B9A1-0FD5ADA898D9

Q28131668-18427FFC-3186-4163-AA48-0A788B4F6E8E

Q28131668-3CDF7B0B-6EFF-41C0-8C59-6D1046E2D8EC

Q28131668-55BB9E39-7776-4BCF-824A-3DA7A8279E70

Q28131668-58DD333F-E7AA-4E64-A970-33FBFD613D9A

Q28131668-6EE3A7F9-65B0-416A-8DD5-26F687CD6371

Q28131668-86C517FC-B598-4CA3-85F8-FF8DBEF0D326

Q28131668-8AB331AA-383A-4652-BFBD-B1AD3FBC7CFA

P304

Q28131668-DF20BC92-9924-4A6D-8924-3C2ED8B18527

P31

Q28131668-9643C459-6CE6-457F-BD5A-C33090430CA6

P3181

Q28131668-360713F7-6F53-4490-B2F4-E7DDEDCCF422

P356

Q28131668-62A717FD-DAAD-4145-AC6C-3AC55228BF67

P407

Q28131668-9F934492-0AA5-49CA-A74B-AAED7A7610BB

P433

Q28131668-F6BB458D-8515-4BB8-AF38-43AFA3520D63

P478

Q28131668-EF65BF8E-B4F3-4E4E-AF49-9119CF8C8C63

P50

Q28131668-B1514F36-08D5-4428-9336-92CEC68CC887

P577

Q28131668-1573016E-1BE9-44DC-B314-C20D67A85F4E

P5875

Q28131668-A13366A2-5EC9-40CA-BD13-26815DD81364

P698

Q28131668-C239E547-6092-4902-8F75-45596629B173

P3181

P356

J.EJCA.2008.10.026

P1433

European Journal of Cancer

P1476

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

@en

P2093

D Lacombe

http://www.w3.org/2001/XMLSchema#string

E A Eisenhauer

http://www.w3.org/2001/XMLSchema#string

J Bogaerts

http://www.w3.org/2001/XMLSchema#string

J Dancey

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

L Dodd

http://www.w3.org/2001/XMLSchema#string

L H Schwartz

http://www.w3.org/2001/XMLSchema#string

L Rubinstein

http://www.w3.org/2001/XMLSchema#string

L Shankar

http://www.w3.org/2001/XMLSchema#string

M Mooney

http://www.w3.org/2001/XMLSchema#string

P304

228-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

28140

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.EJCA.2008.10.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Sargent

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23679331

http://www.w3.org/2001/XMLSchema#string

P698

19097774

http://www.w3.org/2001/XMLSchema#string